[go: up one dir, main page]

FR16C1019I2 - Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases - Google Patents

Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Info

Publication number
FR16C1019I2
FR16C1019I2 FR16C1019C FR16C1019C FR16C1019I2 FR 16C1019 I2 FR16C1019 I2 FR 16C1019I2 FR 16C1019 C FR16C1019 C FR 16C1019C FR 16C1019 C FR16C1019 C FR 16C1019C FR 16C1019 I2 FR16C1019 I2 FR 16C1019I2
Authority
FR
France
Prior art keywords
beta
active
heterocyclic compounds
lactamase inhibitors
lactamase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C1019C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca Holding France SAS
Original Assignee
AstraZeneca Holding France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C1019(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca Holding France SAS filed Critical AstraZeneca Holding France SAS
Publication of FR16C1019I1 publication Critical patent/FR16C1019I1/fr
Application granted granted Critical
Publication of FR16C1019I2 publication Critical patent/FR16C1019I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR16C1019C 2002-01-28 2016-12-13 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases Active FR16C1019I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
PCT/FR2003/000243 WO2003063864A2 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (2)

Publication Number Publication Date
FR16C1019I1 FR16C1019I1 (fr) 2017-02-03
FR16C1019I2 true FR16C1019I2 (fr) 2017-12-29

Family

ID=27619669

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0200951A Expired - Lifetime FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR16C1019C Active FR16C1019I2 (fr) 2002-01-28 2016-12-13 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0200951A Expired - Lifetime FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Country Status (44)

Country Link
US (4) US7612087B2 (fr)
EP (2) EP1480644B1 (fr)
JP (1) JP4472346B2 (fr)
KR (1) KR100979079B1 (fr)
CN (3) CN101406471A (fr)
AR (2) AR038234A1 (fr)
AT (1) ATE484281T1 (fr)
AU (1) AU2003214335B2 (fr)
BE (1) BE2016C069I2 (fr)
BR (1) BRPI0307267B8 (fr)
CA (1) CA2474043C (fr)
CL (1) CL2011000009A1 (fr)
CO (1) CO5601014A2 (fr)
CR (2) CR7387A (fr)
CY (3) CY1111061T1 (fr)
DE (1) DE60334527D1 (fr)
DK (2) DK2279737T3 (fr)
EA (1) EA007220B1 (fr)
EC (1) ECSP045193A (fr)
ES (2) ES2401855T3 (fr)
FR (2) FR2835186B1 (fr)
HR (1) HRP20040686B1 (fr)
HU (1) HUS1600055I1 (fr)
IL (1) IL163167A (fr)
JO (1) JO2646B1 (fr)
LT (1) LTC1480644I2 (fr)
MA (1) MA26351A1 (fr)
MX (1) MXPA04006621A (fr)
MY (1) MY140638A (fr)
NL (1) NL300847I2 (fr)
NO (3) NO335195B1 (fr)
NZ (1) NZ533936A (fr)
OA (1) OA12761A (fr)
PE (1) PE20030969A1 (fr)
PL (1) PL220725B1 (fr)
PT (2) PT1480644E (fr)
RS (1) RS52137B (fr)
SI (2) SI1480644T1 (fr)
TN (1) TNSN04137A1 (fr)
TW (1) TWI293071B (fr)
UA (1) UA80271C2 (fr)
UY (1) UY27626A1 (fr)
WO (1) WO2003063864A2 (fr)
ZA (1) ZA200405607B (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
DK1965798T3 (da) * 2005-12-07 2011-11-28 Basilea Pharmaceutica Ag Nyttige monobactam-antibiotika
EP2040698A4 (fr) * 2006-07-14 2011-08-10 Shionogi & Co Composés d'oximes et leur utilisation
AU2007309195A1 (en) * 2006-10-23 2008-05-02 Irm Llc Cathepsin proteases inhibitors
ES2422603T3 (es) * 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
AU2009206119C1 (en) * 2008-01-18 2016-05-26 Merck Sharp & Dohme Llc Beta-lactamase inhibitors
WO2009114921A1 (fr) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITEURS DE β-LACTAMASES DE CLASSE B ET DE CLASSE D
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
US8518934B2 (en) * 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
JP6266978B2 (ja) 2010-08-10 2018-01-24 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
SG10201510576WA (en) * 2010-12-22 2016-01-28 Meiji Seika Pharma Co Ltd Optically active diazabicyclooctane derivative and process for preparing the same
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
KR102143660B1 (ko) * 2011-06-17 2020-08-11 화이자 안티-인펙티브스 에이비 트랜스-7-옥소-6-(술포옥시)-1,6-디아자비시클로[3,2,1]옥탄-2-카르복스아미드 및 그의 염을 포함하는 헤테로시클릭 화합물의 제조 방법
PL2748165T3 (pl) * 2011-08-27 2017-05-31 Wockhardt Limited Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
WO2013033461A1 (fr) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Dérivés d'ester d'acide boronique hétérocyclique et leurs utilisations thérapeutiques
WO2013038330A1 (fr) * 2011-09-13 2013-03-21 Wockhardt Limited Composés azotés et leur utilisation
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2013237939A1 (en) 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MY174523A (en) 2012-05-30 2020-04-23 Meiji Seika Pharma Co Ltd ?-lactamase inhibitor and process for preparing the same
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3360877B1 (fr) * 2012-08-25 2021-02-17 Wockhardt Limited Derives de 1,6- diazabicyclo [3,2,1]octan- 7- one en tant que composés antibactériens
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201591004A1 (ru) 2013-01-04 2016-02-29 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2014152996A1 (fr) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Forme cristalline d'un inhibiteur de bêta-lactamase
CN105555787B (zh) 2013-09-24 2017-08-08 明治制果药业株式会社 二氮杂二环辛烷衍生物的制备方法及其中间体
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
CA2926071C (fr) 2013-10-08 2021-11-09 Meiji Seika Pharma Co., Ltd. Cristaux de derive de diazabicyclooctane et procede de production de cristaux de derive de diazabicyclooctane
CN106029068A (zh) * 2014-02-20 2016-10-12 沃克哈特有限公司 包含抗菌剂的药物组合
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
PL3604316T3 (pl) 2014-05-05 2024-04-29 Melinta Therapeutics, Inc. Synteza soli boronianowych
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3145936B1 (fr) 2014-05-19 2020-09-30 Qpex Biopharma, Inc. Dérivés d'acide boronique et leurs utilisations thérapeutiques
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
JP6700203B2 (ja) 2014-07-01 2020-05-27 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
MY196240A (en) 2014-11-17 2023-03-24 Entasis Therapeutics Ltd Combination Therapy for Treatment Of Resistant Bacterial Infections
WO2016081297A1 (fr) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Dérivés d'esters d'acide boronique cycliques et leurs utilisations thérapeutiques
AU2015355970B2 (en) 2014-12-05 2020-05-21 Meiji Seika Pharma Co., Ltd. Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112017023359A2 (pt) * 2015-05-07 2018-07-17 Mutabilis ?compostos, composições farmacêuticas e kits?
EP3281942A4 (fr) 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. Inhibiteur de ss-lactamase et son application
JP2018530553A (ja) 2015-10-02 2018-10-18 レゴケム バイオサイエンシズ， インク．Ｌｅｇｏｃｈｅｍ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． β−ラクタマーゼを阻害するための組成物及び方法
WO2017156458A1 (fr) 2016-03-11 2017-09-14 University Of South Florida Inhibiteurs de bêta-lactamases, formulations et utilisations correspondantes
EP3156400B1 (fr) 2016-05-27 2019-05-15 Valoralia I Más D, SL Composés dihydroxadiazines pour le traitement des inféctions et du cancer
JP7060245B2 (ja) 2016-06-30 2022-04-26 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
EP3512851B1 (fr) 2016-09-16 2022-07-06 Entasis Therapeutics Limited Composés inhibiteurs de bêta-lactamase
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
RU2019124705A (ru) 2017-02-06 2021-02-05 Мутабилис Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций
MY201377A (en) 2017-05-08 2024-02-21 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
WO2018234962A1 (fr) 2017-06-20 2018-12-27 Wockhardt Limited Procédé de o-sulfonation de composés 1,6-diazabicyclo[3.2.1]octane
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
WO2019093450A1 (fr) * 2017-11-10 2019-05-16 塩野義製薬株式会社 Dérivé de diazabicyclooctane
CA3097127A1 (fr) 2018-04-20 2019-10-24 Qpex Biopharma, Inc. Derives d'acide boronique et leurs utilisations therapeutiques
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
FI3833665T3 (fi) 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
CN115151544B (zh) * 2020-09-01 2024-08-16 宁夏农林科学院 β-内酰胺酶抑制剂及其制备
WO2022047790A1 (fr) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Composés bicycliques substitués par amidine, leur préparation, leur utilisation comme agents antibactériens et inhibiteurs de bêta-lactamase
EP4146651A4 (fr) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences Composés substitués de sulfonylamidine et leur utilisation en tant qu'inhibiteurs de bêta-lactamase
WO2023060369A1 (fr) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Nouveaux composés bicycliques à substitution carbimidate et leur utilisation en tant qu'inhibiteurs de bêta-lactamase
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (fr) 1986-09-02 1989-02-01 The University Of Melbourne 2-Oxo-4-carboxypyrimidines
AU626427B2 (en) 1989-06-09 1992-07-30 Pharmacia & Upjohn Company Heterocyclic amines having central nervous system activity
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
ES2269528T3 (es) 1993-09-29 2007-04-01 Nabi Nucleosidos y nucleotidos con un anillo heterociclico.
AU699465B2 (en) * 1993-12-29 1998-12-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
EP0702004A2 (fr) 1994-09-15 1996-03-20 Ciba-Geigy Ag Dérivés d'amides d'acide 2,9-diamino- et 2-amino-2-carbamoyl-4-hydroxy-alcanoiques
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
ES2205072T3 (es) * 1996-01-03 2004-05-01 Smithkline Beecham Plc Derivados carbamoiloxi de mutilina y su uso como agentes antibacterianos.
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
EP1070054A1 (fr) 1998-04-08 2001-01-24 Takeda Chemical Industries, Ltd. Composes amines, leur production, et leur utilisation comme antagonistes ou agonistes du recepteur de la somatostatine
EP1091944A1 (fr) 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones et 1,3-benzoxazepin-2-ones utilisees comme inhibiteurs de la reverse-transcriptase du vih
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
AU2347900A (en) 1998-12-18 2000-07-12 Schering Corporation Farnesyl protein transferase inhibitors
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CA2386517A1 (fr) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Derives d'amines
US20030105118A1 (en) 2000-04-18 2003-06-05 Shuji Masumoto Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
ES2287256T3 (es) 2001-02-22 2007-12-16 School Of Pharmacy, University Of London Indolinas y tetrahidroquinolina como profarmacos para el tratamiento de tumores.
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
AR100790A2 (es) 2016-11-02
NO335195B1 (no) 2014-10-20
LTC1480644I2 (lt) 2018-09-10
CL2011000009A1 (es) 2011-03-25
PL371601A1 (pl) 2005-06-27
EP1480644B1 (fr) 2010-10-13
EP2279737A1 (fr) 2011-02-02
KR100979079B1 (ko) 2010-08-31
AU2003214335B2 (en) 2007-04-05
TWI293071B (en) 2008-02-01
CA2474043A1 (fr) 2003-08-07
BR0307267A (pt) 2004-12-07
UA80271C2 (uk) 2007-09-10
NO2016024I1 (no) 2016-12-15
ZA200405607B (en) 2005-09-28
CN1655781A (zh) 2005-08-17
CN100563653C (zh) 2009-12-02
MA26351A1 (fr) 2004-10-01
LTPA2016037I1 (lt) 2017-01-10
JP4472346B2 (ja) 2010-06-02
IL163167A (en) 2010-04-15
US20050020572A1 (en) 2005-01-27
US20100048528A1 (en) 2010-02-25
ECSP045193A (es) 2004-08-27
SI2279737T1 (sl) 2013-07-31
OA12761A (fr) 2006-07-04
BRPI0307267B1 (pt) 2016-02-10
CY1111061T1 (el) 2015-06-11
CR7387A (es) 2010-10-25
CN101406471A (zh) 2009-04-15
SI1480644T1 (sl) 2011-03-31
WO2003063864A2 (fr) 2003-08-07
NO2016024I2 (no) 2016-12-15
EP2279737B1 (fr) 2012-10-31
US7612087B2 (en) 2009-11-03
HK1105864A1 (zh) 2008-02-29
US20110245254A1 (en) 2011-10-06
FR2835186A1 (fr) 2003-08-01
AR038234A1 (es) 2005-01-05
CA2474043C (fr) 2011-08-02
HRP20040686A2 (en) 2004-12-31
HUS1600055I1 (hu) 2017-01-30
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
DE60334527D1 (de) 2010-11-25
FR2835186B1 (fr) 2006-10-20
MY140638A (en) 2010-01-15
BE2016C069I2 (fr) 2022-05-17
ATE484281T1 (de) 2010-10-15
TNSN04137A1 (fr) 2007-03-12
EP1480644A2 (fr) 2004-12-01
PT1480644E (pt) 2011-01-17
CY2016042I2 (el) 2017-03-15
HRP20040686B1 (hr) 2013-02-28
CN100482225C (zh) 2009-04-29
CR20120356A (es) 2012-10-05
CN1994301A (zh) 2007-07-11
CY2016042I1 (el) 2017-03-15
MXPA04006621A (es) 2004-10-04
UY27626A1 (es) 2003-08-29
CY1114417T1 (el) 2016-08-31
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
KR20040081473A (ko) 2004-09-21
RS52137B (sr) 2012-08-31
YU65804A (sh) 2006-08-17
BRPI0307267B8 (pt) 2021-05-25
HK1077205A1 (zh) 2006-02-10
PL220725B1 (pl) 2015-12-31
JP2005523897A (ja) 2005-08-11
EA007220B1 (ru) 2006-08-25
ES2401855T3 (es) 2013-04-25
EA200400981A1 (ru) 2005-02-24
DK2279737T3 (da) 2013-02-11
PT2279737E (pt) 2013-02-01
US20090215747A1 (en) 2009-08-27
FR16C1019I1 (fr) 2017-02-03
NL300847I2 (fr) 2017-01-03
NO20043587L (no) 2004-08-27
ES2356813T3 (es) 2011-04-13
WO2003063864A3 (fr) 2004-03-11
JO2646B1 (en) 2012-06-17
DK1480644T3 (da) 2011-01-24
CO5601014A2 (es) 2006-01-31

Similar Documents

Publication Publication Date Title
FR16C1019I2 (fr) Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
AU2003262023A1 (en) Five-membered heterocyclic compounds
AUPS019702A0 (en) Condensed heterocyclic compounds
AU2003211424A1 (en) Nitrogen-containing heterocyclic compound
AU2003214335A1 (en) Heterocyclic compounds which are active as inhibitors of beta lactamases
PL377087A1 (pl) Związki heterocykliczne
AU2003257094A1 (en) Substituted benzimidazole compounds
AU2003302238A1 (en) 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
AU2003273989A1 (en) Quinazolinone derivatives useful as anti-hyperalgesic agents
IL183590A0 (en) Hydantoin derivatives useful as metalloproteinase inhibitors
AU2002313655A1 (en) 2-(5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl)-succinic acid derivatives as factor viia inhibitors
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
IL164899A0 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
EP1476425A4 (fr) Composes arylsulfonamidobenzyliques heterocycliques
IL164898A0 (en) Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors
AU2003292426A1 (en) Oxazolidinone derivatives as antibacterial agents
IS7833A (is) Efnasambönd með sameinaða heteróhringi
AU2003215635A1 (en) Thiazol-2-yl-imine compounds as pde-7 inhibitors
AU2003280578A1 (en) Heterocyclic compounds
IS8042A (is) Benz[1,2,5]thíadíazól efnasambönd
AU2003215158A1 (en) 2-(5-(5-carbamimidoyl-1h-heteroaryl))-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
AU2003232362A1 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
HK1073465A (en) 5-substituted 1, 1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors
HK1069391A (en) Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors
AU2003900189A0 (en) Heterocyclic derivatives